Regenxbio Inc (NASDAQ: RGNX) stock jumped 2.77% on Monday to $20.03 against a previous-day closing price of $19.49. With 0.61 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.44 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $20.87 whereas the lowest price it dropped to was $19.57. The 52-week range on RGNX shows that it touched its highest point at $25.54 and its lowest point at $12.82 during that stretch. It currently has a 1-year price target of $40.83. Beta for the stock currently stands at 1.29.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RGNX was up-trending over the past week, with a rise of 12.91%, but this was up by 23.95% over a month. Three-month performance surged to 11.22% while six-month performance fell -2.44%. The stock lost -6.09% in the past year, while it has lost -11.68% so far this year. A look at the trailing 12-month EPS for RGNX yields -5.98 with Next year EPS estimates of -2.89. For the next quarter, that number is -1.16. This implies an EPS growth rate of 17.99% for this year and 45.71% for next year. EPS is expected to grow by 13.60% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -21.54%.
Float and Shares Shorts:
At present, 43.30 million RGNX shares are outstanding with a float of 39.81 million shares on hand for trading. On Oct 30, 2023, short shares totaled 4.14 million, which was 9.41% higher than short shares on Sep 28, 2023. In addition to Mr. Kenneth T. Mills as the firm’s President, CEO & Director, Mr. Vittal K. Vasista serves as its Executive VP & CFO.
Institutional Ownership:
Through their ownership of 92.97% of RGNX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 48.23% of RGNX, in contrast to 40.65% held by mutual funds. Shares owned by individuals account for 20.22%. As the largest shareholder in RGNX with 14.98% of the stake, BlackRock Fund Advisors holds 6,586,138 shares worth 6,586,138. A second-largest stockholder of RGNX, The Vanguard Group, Inc., holds 4,312,317 shares, controlling over 9.81% of the firm’s shares. Redmile Group LLC is the third largest shareholder in RGNX, holding 2,574,042 shares or 5.86% stake. With a 6.18% stake in RGNX, the iShares Core S&P Small Cap ETF is the largest stakeholder. A total of 2,718,129 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 2.82% of RGNX stock, is the second-largest Mutual Fund holder. It holds 1,239,237 shares valued at 15.97 million. JPMorgan Small Cap Growth Fund holds 2.61% of the stake in RGNX, owning 1,148,829 shares worth 14.81 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RGNX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With RGNX analysts setting a high price target of $65.00 and a low target of $20.00, the average target price over the next 12 months is $40.83. Based on these targets, RGNX could surge 224.51% to reach the target high and fall by -0.15% to reach the target low. Reaching the average price target will result in a growth of 103.84% from current levels.
Summary of Insider Activity:
Insiders traded RGNX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 15 while that of sell transactions has risen to 7 over the past year. The total number of shares bought during that period was 456,218 while 21,593 shares were sold.
